Quest Diagnostics, Inc. (DGX) Tops Q3 EPS by 7c; Guides FY11 EPS Above Views
Tweet
Share
E-mailGet Alerts DGX Hot Sheet
Price: $235.50 -0.69%
EPS Growth %: +10.0%
Financial Fact:
Operating income: 322M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +10.0%
Financial Fact:
Operating income: 322M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Quest Diagnostics, Inc. (NYSE: DGX) reported Q3 EPS of $1.18, $0.07 better than the analyst estimate of $1.11. Revenue for the quarter came in at $1.9 billion versus the consensus estimate of $1.89 billion.
Quest Diagnostics, Inc. sees FY2011 EPS of $4.30-$4.35, versus the consensus of $4.21. Sees revenues growing 1.5%, unchanged from previous guidance
Quest Diagnostics, Inc. sees FY2011 EPS of $4.30-$4.35, versus the consensus of $4.21. Sees revenues growing 1.5%, unchanged from previous guidance
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Quest Diagnostics (DGX) PT Raised to $245 at UBS
- GameStop (GME) Tops Q2 EPS by 8c
- Samsara Inc (IOT) Tops Q2 EPS by 4c, Beats on Revenue; Offers Q3 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
